In Science, researchers described an AI-designed synthetic TnpB enzyme (SynTnpBs) that outperformed a natural reference transposase. The advance extends beyond standard CRISPR-Cas systems by adding a new gene-editing capability with distinct properties. The approach addresses a core limitation of existing genome-editing toolkits: many available enzymes already evolved in nature and may not cover the performance characteristics needed for specific applications. By designing new enzymes, the team broadened the set of editing options for future therapeutics. For biotech developers, new enzyme families can enable improved targeting, reduced off-target activity, or different delivery and editing constraints depending on downstream validation.